Q-omics provides the consensus-scored SNORA26 profile across patient tissues and cancer cell-line models. SNORA26 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SNORA26 is differentially expressed in 14, with the highest sampling consensus in BLCA. Additionally, SNORA26 RNA expression shows 16,383 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, BLCA, and UVM as cancer lineages where SNORA26 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNORA26 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNORA26 survival associations across molecular data types. SNORA26 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNORA26 RNA expression–survival associations across cancer types. High SNORA26 expression shows unfavorable associations in KIRC, UVM and ACC, but favorable associations in BLCA, UCS and MESO. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SNORA26 RNA expression.
This table summarizes SNORA26 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for SNORA26. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNORA26 shows higher tumor expression in BLCA, LUAD, STAD, HNSC, LIHC and LUSC. The BLCA box plot shows higher SNORA26 RNA expression in tumor versus normal tissue (log2 FC = +1.629, t-test p = .002).
This table shows molecular features associated with SNORA26 in patient tissues and cancer cell lines. In patient samples, SNORA26 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
